ERAL1 and breast neoplasm: This study supports data of clinical trials showing the efficacy of tamoxifen not only on ERα-positive breast tumors where it acts by competing with E2 for binding to the ER in the tumor tissue, but also in breast tumors without ER where 5-10% response rate has been reported 3, 4.